
# Hematology Case Conference




# Flow Cytometry Case: 03-120-0366 Patient: Rxxx L Mxxx

- WBC= 37.9, Hgb=11.2.0, Plt=135,000, MCV= 73.7 Seg 45, Lymph 55


# **Peripheral Blood Smear**




# **Peripheral Blood Smear (cont'd)**




# **Peripheral Blood Smear (cont'd)**




#### **Peripheral Blood Smear** (with Albumin)




#### Peripheral Blood Smear (with Albumin), cont'd




#### Peripheral Blood Smear (with Albumin), cont'd




#### Basic Components of Flow Cytometry







Forward scatter: measures cell size

Side scatter: measures cell complexity






#### Plotting of Marker Results




CD5




# **Flow Cytometry**


































### Diagnosis


- Flow cytometry: -Pos: CD5, CD20, CD23, kappa light chain restriction -Neg:CD10, FMC7
- DX: chronic lymphocytic leukemia

# 03-113-0227 Patient Name: Yxxx, Fxxx


- 69 y/o male with anemia, thrombocytopenia
  WBC=5, Hgb=5.1, Plt=89K, LDH=253
- Peripheral blood smear shows Plasmodium falciparum, parasitic load 17%.
- Underwent red cell exchanges
- Gametocytes seen in blood smear 6 days after treatment




# **Peripheral Blood Smear**




# **Peripheral Blood Smear (cont'd)**



### Peripheral Blood Smear, 6 days after tx



# Peripheral Blood Smear, 6 days after tx, cont'd






#### Gametocytes

- Some individual intracellular merozoites assume sexual forms (gametocytes). These do not lyse red cells and do not divide while in blood. They will proliferate only if ingested by a female anopheles mosquito (fertilization occurs in the mosquito's abdominal cavity to prduce sporozoites)
- Gametocytes are sometimes seen after treatment. Peripheral blood should be monitored only for asexual forms.



# **Plasmodial Life Cycle**






#### Treatment

- Uncomplicated malaria infection: chloroquine
- Resistance P. Falciparum: quinine or quinidine
- Severe P. Faliciparum:
  - Cerebral malaria (coma, seizure), renal failure, resp distress,
    DIC-> quinidine gluconate IV
  - Red cell exchange if parasitic load > 10% (5-10% may be considered in pts with severe Sx). Typ 4-17 units of RBCs.
     Note that patients in endemic areas may develop semiimmune status and do not have severe Sx with high parasitic load




# HS-03-2902 Patient Name: Dxxx Oxxx

- 8 y/o male with (L) neck mass
- Tissue submitted: (L) cervical lymph node




# Lymph Node biopsy







# Lymph Node biopsy (cont'd)



# Lymph Node biopsy (cont'd)



# Lymph Node biopsy (cont'd)





# Diagnosis

Immunostains:
 R-S cells and Hodgkin cells are
 -Pos: CD15, CD30
 -Neg: CD20, CD45 (LCA)

- Flow cytometry: T cells with no aberrant expression, B cells without light-chain restriction
- Numerous lymphocytes, moderate R-S cells, no lacunar cells, no fibrotic septa -> Classic Hodgkin lymphoma, lymphocyterich



# **Diagnosis (cont'd)**

Classic Hodgkin lymphoma :

-95% of all Hodgkin lymphoma

-Bimodal age: peak at 15-35, second peak in late life

-Involves cervical LN (75%), followed by mediastinal, axilliary, and para-aortic LN

-EBV is postulated to play a role in pathogeneis


-Subtypes:

(1) Nodular sclerosis: 70%

(2) Mixed cellularity: 20-25%

(3) Lymphocyte-rich: 5% (median age is higher than in other subtypes)

(4) Lymphocyte-depleted: < 5%




# HB-03-55 Patient Name: Hxxx, Yxxx


- 54 year old Hispanic female newly diagnosed with HIV, cryptococcal meningitis.
- CBC: WBC=6.3, Hgb=11.1, Plt=74k, rare NRBCs
- Bone marrow to investigate thrombocytopenia: bx 40% cellularity, increase in megakaryocytes




## **Bone Marrow Biopsy**












#### Bone Marrow Biopsy-Gomori Methenamine Silver Stain




## **Bone Marrow Biopsy-GMS Stain, cont'd**



## **Bone Marrow Biopsy- Mucin Stain**



#### **Bone Marrow Biopsy- Mucin Stain, cont'd**






## HB-03-58 Patient Name: Sxxx, Bxxx


- 31 year old white female with AIDS and persistent fever.
  Patient had been diagnosed with MAI in sputum (1/03). Now sputum, CSF and blood cultures are negative
- CBC: WBC=3, Hbg=7, Plt=403k
- Bone marrow was requested by ID: bx 75% cellularity




## **Bone Marrow Biopsy**











### **Bone Marrow Biopsy-AFB Stain**



### **Bone Marrow Biopsy-AFB Stain**



# 03-108-0589 Patient: Axxx, Mxxx

- 50 y/o Iranian male who was evaluated for cholecystectomy at Memorial City Hospital. Patient allegedly has a Hx of hemophilia A with no Hx of frank bleeding tendency. Patient had also been told to have von Willebrand disease.
- Past medical history: in 1982, patient underwent toot extraction at which time he was given some type of fluid (?) to prevent bleeding.
- Family Hx: mother and sister (in Iran) with hemophilia (?)




#### **Laboratory Tests**

- PT= 11.0 sec (ref 8-11.5)
  PTT= 45.9 sec (ref 24.0-37.5)
- F VIII=8% (ref 46-182)
  vWF:RCo=31% (ref 45-140%)
  vWF:Ag=35% (ref 45-165%)

Differential diagnosis:
 (1) Hemophilia A: low vWF (?), Hx of hemophilia in mother, and sister (?)
 (2) vWD: low F VIII (?)



## F VIII-vWF Complex



#### **2N-von Willebrand Disease**

- A rare subtype 2 of vWD. "N" stands for Normandy, France where the first case was described in 1989
- In 2N-vWD, vWF does not bind adequately to FVIII. As a result, F VIII level is low due to a shorter half-life
- vWF level can be normal or moderately low
- 2N-vWD is frequently misdiagnosed as hemophilia A in a male patient. Subsequent family studies show autosomal-recessive inheritance (not sex-linked as in hemophilia)
- At least 5 coding defects of vWF gene (Gene map locus 12p 13.3) has been found to be a/w 2N-vWD
- In several family studies showed compound heterozygous with both type I and and type 2N

#### **2N-von Willebrand Disease: Laboratory Tests**

- F VIII level is disproportinally depressed compared to vWF level which is either normal or moderately depressed
- F VIII-vWF Binding Assay (Blood Center, Milwaukee, WI, \$275):
  - Capturing pt's vWF in a microtiter well coated with monoclonal Ab to vWF
  - Strip off pt's F VIII with 0.4M Calcium chloride
  - Allow pt's vWF to bind to recombinant F VIII
  - The bound F VIII is quantitated by chromogenic assay
  - Reported ratio of (bound F VIII / pt's vWF)
    Typical ref range: >60%

#### **2N-von Willebrand Disease: Treatment**

- 2N-vWD patient has very short correction of F VIII in response to F VIII replacement or DDAVP.
- Optimal therapy: F VIII/vWF concentrates (Humate P, Alphanate, Koate HP)
- Patient responded well to Tx: F VIII= 156% vWF:RCo=214%